What Are the Warning Signs You're Losing Muscle, Not Just Fat, on a GLP-1 Medication?
What Are the Warning Signs You're Losing Muscle, Not Just Fat, on a GLP-1 Medication?
The clearest early warning signs are a declining grip strength, a falling chair-stand count, and everyday tasks — stairs, carrying groceries, standing up from a low seat — starting to feel harder despite continued weight loss. These are the same measures used clinically to screen for sarcopenia, and they tend to show change before the scale, or a mirror, would suggest anything is wrong.
Why can’t the scale tell you this
Weight loss on a GLP-1 medication is a combined measure of fat and lean tissue loss, and the proportion varies significantly by individual. Two people can lose the same amount of weight — one losing mostly fat, the other losing a meaningful share of muscle alongside it — and the scale would show an identical number for both. Functional and strength-based measures are what separate these two very different outcomes.
The grip strength test
Handgrip strength, measured with a simple dynamometer, is considered a gold-standard screening measure for sarcopenia in clinical research and is one of the criteria used in the widely referenced European Working Group on Sarcopenia in Older People (EWGSOP2) diagnostic framework. A noticeable decline in grip strength — a jar that used to open easily, a struggle to carry a bag that wasn't a problem a month ago — is one of the most sensitive early indicators available without lab equipment.
The chair-stand test
The 30-second chair stand test (counting how many times you can rise from a seated position without using your hands in 30 seconds) and the related five-times sit-to-stand test are widely used, validated proxies for lower-body muscle strength and physical performance. Research comparing chair-stand performance to grip strength found that the two tests identify overlapping but not identical groups of people with declining muscle function — using both together catches more cases than either alone.
Gait speed and the stairs test
Walking speed is one of the most studied predictors of functional decline; a pace below approximately 0.8 meters per second (roughly 2.6 feet per second) is treated as a meaningful clinical threshold in sarcopenia assessment. In everyday terms, this often shows up as being the last one to cross an intersection before the light changes, or needing to grip a stair railing and pull rather than simply stepping up.
A five-question self-check: the SARC-F
Clinicians frequently use a short self-report tool called the SARC-F to screen for sarcopenia risk, asking about difficulty with strength, walking assistance, rising from a chair, climbing stairs, and falls, each scored from no difficulty to a lot of difficulty (Malmstrom et al., as validated in multiple cohort studies). A rising score across these five simple questions — even without any formal testing — is a reasonable signal to bring the topic to your prescribing provider.
What to do if you notice these signs
None of these signs on their own mean something has gone wrong. They're signals worth tracking over several weeks, not single data points to react to immediately. If a downward trend holds across two or more check-ins, that's the point to raise it directly with your prescribing provider — particularly alongside a review of your current protein intake and resistance training frequency, the two levers most directly tied to preserving muscle during GLP-1 treatment.
For the protein target that supports this, see: How Much Protein Do You Actually Need on a GLP-1 Medication to Protect Muscle?
For the training frequency that supports this, see: How Often Should You Strength Train on a GLP-1 Medication to Protect Muscle?
Continue With the Protein & Strength Record Series
This article is the third in a three-part series on protein, resistance training, and muscle preservation during GLP-1 treatment:
1. How Much Protein Do You Actually Need on a GLP-1 Medication to Protect Muscle?
2. How Often Should You Strength Train on a GLP-1 Medication to Protect Muscle?
3. What Are the Warning Signs You're Losing Muscle, Not Just Fat, on a GLP-1? (this article)
If this raised more questions than it answered, the companion essay, Why Does the Weight Come Off But the Strength Doesn't Show Up? (Kindle, $2.99) walks through why this happens in plain, non-clinical language.
To track your own protein, function, and weight side by side, see the Protein & Strength Record (paperback companion log).
Not sure this is the right tool for your question? Which Log Fits Your Question →
Browse the full Observation Tools catalog.
Sources
Malmstrom, T. K., et al. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. As validated in cross-sectional cohort studies of community-dwelling older adults.
Performance on sit-to-stand tests in relation to measures of functional fitness and sarcopenia diagnosis in community-dwelling older adults. European Review of Aging and Physical Activity.
European Working Group on Sarcopenia in Older People 2 (EWGSOP2) diagnostic criteria, as referenced in geriatric rehabilitation and community-dwelling adult cohort studies.
Gait speed as a sarcopenia and functional decline threshold (~0.8 m/s), as referenced in Short Physical Performance Battery (SPPB) sarcopenia staging literature.
Ozempic®, Wegovy®, Mounjaro®, and Zepbound® are registered trademarks of their respective manufacturers. Sacred Books, LLC is not affiliated with, sponsored by, or endorsed by these manufacturers.
